|
gptkbp:instanceOf
|
gptkb:naphthoylindole
gptkb:synthetic_cannabinoid
|
|
gptkbp:actsOn
|
CB1 receptor agonist
CB2 receptor agonist
|
|
gptkbp:binding_affinity_(CB1)
|
0.46 nM
|
|
gptkbp:binding_affinity_(CB2)
|
0.69 nM
|
|
gptkbp:CASNumber
|
824959-81-1
|
|
gptkbp:category
|
gptkb:recreational_drug
gptkb:naphthoylindole
gptkb:cannabinoid_receptor_agonist
|
|
gptkbp:chemicalFormula
|
C24H23NO
|
|
gptkbp:discoveredBy
|
gptkb:John_W._Huffman
|
|
gptkbp:IUPACName
|
4-ethyl-1-naphthalenyl-(1-pentyl-1H-indol-3-yl)-methanone
|
|
gptkbp:legal_status_(Germany)
|
Anlage II controlled substance
|
|
gptkbp:legal_status_(United_Kingdom)
|
Class B drug
|
|
gptkbp:legal_status_(United_States)
|
Schedule I controlled substance
|
|
gptkbp:molecularWeight
|
341.45 g/mol
|
|
gptkbp:namedAfter
|
gptkb:John_W._Huffman
|
|
gptkbp:relatedTo
|
gptkb:JWH-018
gptkb:JWH-073
gptkb:JWH-122
|
|
gptkbp:routeOfAdministration
|
oral
inhalation
|
|
gptkbp:used_in
|
gptkb:scientific_research
|
|
gptkbp:bfsParent
|
gptkb:JWH_cannabinoids
|
|
gptkbp:bfsLayer
|
6
|
|
https://www.w3.org/2000/01/rdf-schema#label
|
JWH-210
|